DXC Stockholders Reject Employee Equity Plan Expansion, Narrowly Approve Say-on-Pay
DXC sits 19% above its 52-week low of $7.9.
Summary
DXC Technology's stockholders rejected a proposal to increase shares available for employee equity awards, while narrowly approving executive pay and director plan expansion. The votes reflect strong investor pushback against dilution and compensation practices.
Key Events · Corporate Governance and Compliance · DXC
-
Employee Equity Plan Expansion Rejected
Proposal 4, which sought to extend the term and increase shares under the 2017 Omnibus Incentive Plan, failed with 49.8M votes for and 67.9M against. This blocks potential dilution from new employee equity grants.
-
Say-on-Pay Passes by Razor-Thin Margin
The advisory vote on executive compensation (Proposal 3) received 58.9M votes for and 58.9M against — a margin of fewer than 83,000 votes — indicating strong investor discontent with pay practices.
-
Director Equity Plan Approved
Proposal 5, extending and increasing shares for the Non-Employee Director Incentive Plan, passed with 104.6M votes for and 13.3M against, allowing continued equity compensation for board members.
-
All Nine Directors Elected
Each director nominee received at least 110M votes for, with no significant opposition, ensuring board continuity.
Analysis · DXC · Technology
At DXC's annual meeting, stockholders rejected a proposal to add shares to the employee incentive plan — a direct rebuke to management's compensation strategy. The say-on-pay vote passed by fewer than 83,000 votes out of 118 million cast, signaling deep investor dissatisfaction. Meanwhile, a separate plan for non-employee directors was approved. These results, coming just two months after the proxy filing highlighted potential 29.7% dilution, suggest shareholders are drawing a hard line against further equity compensation dilution for employees, even as they support director compensation. The failed proposal removes a near-term dilution overhang but also limits the company's ability to use equity to retain talent amid a challenging turnaround.
At the time of this filing, DXC was trading at $9.41 on NYSE in the Technology sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.90 to $15.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.